Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron infusion vs bolus for CINV
NCT02557035Phase 3Completed
- Sponsor
- Helsinn
- Start
- Oct 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Helsinn. Primary endpoint: Percentage of Patients With Complete Response (CR) in the Acute Phase. Started Oct 2015; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02557035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557035.